Stock Movers: Novo Nordisk Pill Approval, Ryanair Fine, Akzo Nobel Activist Stake

Novo Nordisk's Obesity Drug Advances

• 💊 Novo Nordisk has secured US approval for a pill version of its Wegovy obesity drug, a significant move to defend market share.
• 📈 Shares surged approximately 7% on the news, with sales set to begin in January at $149 per month.
• ⚔️ This development is seen as a crucial step in its competition with rival Eli Lilly, whose own pill version is anticipated in March.

Ryanair Faces Italian Antitrust Fine

• ⚖️ Ryanair has been fined over €255 million by Italy's antitrust watchdog for allegedly hindering third-party travel agencies.
• 🚫 The airline is accused of abusing its dominant market position by obstructing agencies from booking flights on its website.
• ✊ Ryanair has announced its intention to appeal the fine, citing a strained relationship with Italian authorities.

Cevian Capital Increases Akzo Nobel Stake

• 📈 Cevian Capital, an activist investor, has raised its stake in Akzo Nobel NV to 10.15% from approximately 5%.
• 🎯 This increased holding signals support for Akzo Nobel's strategy overhaul and turnaround efforts, which include cost-cutting and job reductions.
• 🚀 Cevian Capital has a history of driving significant changes within the companies it invests in, potentially leading to further restructuring at Akzo Nobel.